News | May 30, 2023
Hikal posts FY23 PAT at Rs. 36 Cr
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
This is the second US FDA GMP inspection of this facility within one year
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
The facility will have a capacity to manufacture upto 3 million tubes monthly
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Pheezee is designed to assess musculoskeletal and neuromuscular health.
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
Subscribe To Our Newsletter & Stay Updated
